Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
National Hospital for Neurology and Neurosurgery, Queen Square, London
National Hospital for Neurology and Neurosurgery, Queen Square, London
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.